mention stringlengths 1 105 | mention_text stringclasses 989
values | entity stringlengths 3 73 | aliases stringlengths 4 500 | definition stringlengths 0 935 | id stringlengths 12 12 |
|---|---|---|---|---|---|
locomotor hyperactivity | The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and t... | Movement Disorders | Dyskinesia Syndrome Syndromes Lingual-Facial-Buccal Linguofacial Oral Oral-facial Orofacial Tardive Dyskinesias Dystonia Dystonias Etat Marbre Lingual Facial Buccal Movement Disorder Disorders facial Status Marmoratus | Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| MESH:D009069 |
cocaine | The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and t... | Cocaine | Cocaine HCl Hydrochloride | An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, lik... | MESH:D003042 |
GR 55562 | The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and t... | 3-(3-(dimethylamino)propyl)-4-hydroxy-N-(4-(4-pyridinyl)phenyl)benzamide | 3-(3-(dimethylamino)propyl)-4-hydroxy-N-(4-(4-pyridinyl)phenyl)benzamide GR 55562 GR-55562 GR55562 | MESH:C103477 | |
CP 93129 | The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and t... | 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one | 3-(1,2,5,6-tetrahydropyrid-4-yl)pyrrolo(3,2-b)pyrid-5-one CP 93129 CP-93,129 | MESH:C065046 | |
hyperlocomotion | The present study was designed to examine the effect of 5-HT1B receptor ligands microinjected into the subregions of the nucleus accumbens (the shell and the core) on the locomotor hyperactivity induced by cocaine in rats. Male Wistar rats were implanted bilaterally with cannulae into the accumbens shell or core, and t... | Movement Disorders | Dyskinesia Syndrome Syndromes Lingual-Facial-Buccal Linguofacial Oral Oral-facial Orofacial Tardive Dyskinesias Dystonia Dystonias Etat Marbre Lingual Facial Buccal Movement Disorder Disorders facial Status Marmoratus | Syndromes which feature DYSKINESIAS as a cardinal manifestation of the disease process. Included in this category are degenerative, hereditary, post-infectious, medication-induced, post-inflammatory, and post-traumatic conditions.
| MESH:D009069 |
Ticlopidine | Ticlopidine-induced cholestatic hepatitis. | Ticlopidine | 53 32C 53-32C 5332C Almirall Brand of Ticlopidine Hydrochloride Roche Ticlid Ticlodix Ticlodone Vitoria | An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
| MESH:D013988 |
cholestatic | Ticlopidine-induced cholestatic hepatitis. | Cholestasis | Bile Duct Obstruction Obstructions Biliary Stases Stasis Cholestases Cholestasis | Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| MESH:D002779 |
hepatitis | Ticlopidine-induced cholestatic hepatitis. | Drug-Induced Liver Injury | Acute Liver Injury Drug Induced Drug-Induced Disease Diseases Hepatitides Hepatitis Injuries Toxic | A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
| MESH:D056486 |
ticlopidine | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Ticlopidine | 53 32C 53-32C 5332C Almirall Brand of Ticlopidine Hydrochloride Roche Ticlid Ticlodix Ticlodone Vitoria | An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
| MESH:D013988 |
cholestatic | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Cholestasis | Bile Duct Obstruction Obstructions Biliary Stases Stasis Cholestases Cholestasis | Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| MESH:D002779 |
hepatitis | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Drug-Induced Liver Injury | Acute Liver Injury Drug Induced Drug-Induced Disease Diseases Hepatitides Hepatitis Injuries Toxic | A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
| MESH:D056486 |
Cholestatic | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Cholestasis | Bile Duct Obstruction Obstructions Biliary Stases Stasis Cholestases Cholestasis | Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| MESH:D002779 |
jaundice | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Jaundice | Hemolytic Jaundice Jaundices Icterus | A clinical manifestation of HYPERBILIRUBINEMIA, characterized by the yellowish staining of the SKIN; MUCOUS MEMBRANE; and SCLERA. Clinical jaundice usually is a sign of LIVER dysfunction.
| MESH:D007565 |
Hepatitis | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Drug-Induced Liver Injury | Acute Liver Injury Drug Induced Drug-Induced Disease Diseases Hepatitides Hepatitis Injuries Toxic | A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
| MESH:D056486 |
cholestasis | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Cholestasis | Bile Duct Obstruction Obstructions Biliary Stases Stasis Cholestases Cholestasis | Impairment of bile flow due to obstruction in small bile ducts (INTRAHEPATIC CHOLESTASIS) or obstruction in large bile ducts (EXTRAHEPATIC CHOLESTASIS).
| MESH:D002779 |
hepatotoxicity | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | Drug-Induced Liver Injury | Acute Liver Injury Drug Induced Drug-Induced Disease Diseases Hepatitides Hepatitis Injuries Toxic | A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, and chemicals from the environment.
| MESH:D056486 |
clopidogrel | OBJECTIVE: To report 2 cases of ticlopidine-induced cholestatic hepatitis, investigate its mechanism, and compare the observed main characteristics with those of the published cases. CASE SUMMARIES: Two patients developed prolonged cholestatic hepatitis after receiving ticlopidine following percutaneous coronary angiop... | clopidogrel | BMS brand 1 of clopidogrel bisulfate 2 Iscover PCR 4099 PCR-4099 Plavix SC 25989C 25990C SR 25989 Sandoz besylate hydrochloride napadisilate (+)(S)-isomer clopidogrel-Mepha | MESH:C055162 | |
sodium | Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome. | Sodium | Ion Level Sodium | A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
| MESH:D012964 |
puromycin aminonucleoside | Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome. | Puromycin Aminonucleoside | 3' Amino 3' deoxy N,N dimethyladenosine 3'-Amino-3'-deoxy-N,N-dimethyladenosine Aminonucleoside Puromycin | PUROMYCIN derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. It is an antibiotic with antineoplastic properties and can cause nephrosis.
| MESH:D011692 |
nephrotic syndrome | Epithelial sodium channel (ENaC) subunit mRNA and protein expression in rats with puromycin aminonucleoside-induced nephrotic syndrome. | Nephrotic Syndrome | Nephrotic Syndrome Syndromes | A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dys... | MESH:D009404 |
nephrotic syndrome | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Nephrotic Syndrome | Nephrotic Syndrome Syndromes | A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dys... | MESH:D009404 |
sodium | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Sodium | Ion Level Sodium | A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
| MESH:D012964 |
puromycin aminonucleoside | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Puromycin Aminonucleoside | 3' Amino 3' deoxy N,N dimethyladenosine 3'-Amino-3'-deoxy-N,N-dimethyladenosine Aminonucleoside Puromycin | PUROMYCIN derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. It is an antibiotic with antineoplastic properties and can cause nephrosis.
| MESH:D011692 |
PAN | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Puromycin Aminonucleoside | 3' Amino 3' deoxy N,N dimethyladenosine 3'-Amino-3'-deoxy-N,N-dimethyladenosine Aminonucleoside Puromycin | PUROMYCIN derivative that lacks the methoxyphenylalanyl group on the amine of the sugar ring. It is an antibiotic with antineoplastic properties and can cause nephrosis.
| MESH:D011692 |
aldosterone | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Aldosterone | Aldosterone (+-)-Isomer (11 beta,17 alpha)-Isomer | A hormone secreted by the ADRENAL CORTEX that regulates electrolyte and water balance by increasing the renal retention of sodium and the excretion of potassium.
| MESH:D000450 |
proteinuria | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Proteinuria | Proteinuria Proteinurias | The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| MESH:D011507 |
Sodium | In experimental nephrotic syndrome, urinary sodium excretion is decreased during the early phase of the disease. The molecular mechanism(s) leading to salt retention has not been completely elucidated. The rate-limiting constituent of collecting duct sodium transport is the epithelial sodium channel (ENaC). We examined... | Sodium | Ion Level Sodium | A member of the alkali group of metals. It has the atomic symbol Na, atomic number 11, and atomic weight 23.
| MESH:D012964 |
NO | NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. | Nitric Oxide | Endogenous Nitrate Vasodilator Endothelium-Derived Nitric Oxide Mononitrogen Monoxide Nitrogen Endothelium Derived | A free radical gas produced endogenously by a variety of mammalian cells, synthesized from ARGININE by NITRIC OXIDE SYNTHASE. Nitric oxide is one of the ENDOTHELIUM-DEPENDENT RELAXING FACTORS released by the vascular endothelium and mediates VASODILATION. It also inhibits platelet aggregation, induces disaggregation of... | MESH:D009569 |
migraine | NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. | Migraine Disorders | Abdominal Migraine Migraines Acute Confusional Cervical Syndrome Syndromes Disorder Disorders Headache Sick Headaches Hemicrania Variant Variants Status Migrainosus | A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| MESH:D008881 |
calcitonin gene-related peptide | NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. | Calcitonin Gene-Related Peptide | Calcitonin Gene Related Peptide I II Gene-Related alpha CGRP alpha-CGRP beta beta-CGRP | Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple bio... | MESH:D015740 |
CGRP | NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. | Calcitonin Gene-Related Peptide | Calcitonin Gene Related Peptide I II Gene-Related alpha CGRP alpha-CGRP beta beta-CGRP | Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple bio... | MESH:D015740 |
serotonin | NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. | Serotonin | 3-(2-Aminoethyl)-1H-indol-5-ol 5 Hydroxytryptamine 5-HT 5-Hydroxytryptamine Enteramine Hippophaine Serotonin | A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, ... | MESH:D012701 |
calcitonin gene-related peptide | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Calcitonin Gene-Related Peptide | Calcitonin Gene Related Peptide I II Gene-Related alpha CGRP alpha-CGRP beta beta-CGRP | Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple bio... | MESH:D015740 |
CGRP | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Calcitonin Gene-Related Peptide | Calcitonin Gene Related Peptide I II Gene-Related alpha CGRP alpha-CGRP beta beta-CGRP | Calcitonin gene-related peptide. A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in neural tissue of the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple bio... | MESH:D015740 |
serotonin | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Serotonin | 3-(2-Aminoethyl)-1H-indol-5-ol 5 Hydroxytryptamine 5-HT 5-Hydroxytryptamine Enteramine Hippophaine Serotonin | A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, ... | MESH:D012701 |
5-hydroxytriptamine | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Serotonin | 3-(2-Aminoethyl)-1H-indol-5-ol 5 Hydroxytryptamine 5-HT 5-Hydroxytryptamine Enteramine Hippophaine Serotonin | A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, ... | MESH:D012701 |
5-HT | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Serotonin | 3-(2-Aminoethyl)-1H-indol-5-ol 5 Hydroxytryptamine 5-HT 5-Hydroxytryptamine Enteramine Hippophaine Serotonin | A biochemical messenger and regulator, synthesized from the essential amino acid L-TRYPTOPHAN. In humans it is found primarily in the central nervous system, gastrointestinal tract, and blood platelets. Serotonin mediates several important physiological functions including neurotransmission, gastrointestinal motility, ... | MESH:D012701 |
headache | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Headache | Bilateral Headache Headaches Cephalalgia Cephalalgias Cephalgia Cephalgias Cephalodynia Cephalodynias Cranial Pain Pains Generalized Head Ocular Orthostatic Periorbital Retro-Ocular Sharp Throbbing Unilateral Vertex Hemicrania Retro | The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.
| MESH:D006261 |
migraine | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Migraine Disorders | Abdominal Migraine Migraines Acute Confusional Cervical Syndrome Syndromes Disorder Disorders Headache Sick Headaches Hemicrania Variant Variants Status Migrainosus | A class of disabling primary headache disorders, characterized by recurrent unilateral pulsatile headaches. The two major subtypes are common migraine (without aura) and classic migraine (with aura or neurological symptoms). (International Classification of Headache Disorders, 2nd ed. Cephalalgia 2004: suppl 1)
| MESH:D008881 |
nitroglycerin | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Nitroglycerin | Anginine Dynamite Gilustenon Glyceryl Trinitrate Nitrangin Nitro Bid Dur Nitro-Bid Nitro-Dur NitroBid NitroDur Nitrocard Nitroderm TTS Nitroglycerin Nitroglyn Nitrol Nitrolan Nitrong Nitrospan Nitrostat Perlinganit Susadrin Sustac Sustak Sustonit Transderm Tridil Trinitrin Trinitrolong | A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.
| MESH:D005996 |
migraineurs (without aura) | The aim of the present study was to investigate changes in the plasma calcitonin gene-related peptide (CGRP) concentration and platelet serotonin (5-hydroxytriptamine, 5-HT) content during the immediate headache and the delayed genuine migraine attack provoked by nitroglycerin. Fifteen female migraineurs (without aura)... | Migraine without Aura | Common Migraine Migraines without Aura | Recurrent unilateral pulsatile headaches, not preceded or accompanied by an aura, in attacks lasting 4-72 hours. It is characterized by PAIN of moderate to severe intensity; aggravated by physical activity; and associated with NAUSEA and / or PHOTOPHOBIA and PHONOPHOBIA. (International Classification of Headache Disord... | MESH:D020326 |
Coronary aneurysm | Coronary aneurysm after implantation of a paclitaxel-eluting stent. | Coronary Aneurysm | Aneurysm Coronary Aneurysms | Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.
| MESH:D003323 |
paclitaxel | Coronary aneurysm after implantation of a paclitaxel-eluting stent. | Paclitaxel | 7 epi Taxol 7-epi-Taxol Anzatax Bris Bristol-Myers Brand of Paclitaxel Squibb Bull Ivax Lemery NSC 125973 NSC-125973 NSC125973 Onxol (4 alpha)-Isomer Paxene Praxel A | A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| MESH:D017239 |
coronary aneurysm | Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture. We present a 43-y... | Coronary Aneurysm | Aneurysm Coronary Aneurysms | Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.
| MESH:D003323 |
aneurysm | Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture. We present a 43-y... | Aneurysm | Aneurysm Fusiform Aneurysms Saccular | Pathological outpouching or sac-like dilatation in the wall of any blood vessel (ARTERIES or VEINS) or the heart (HEART ANEURYSM). It indicates a thin and weakened area in the wall which may later rupture. Aneurysms are classified by location, etiology, or other characteristics.
| MESH:D000783 |
thrombosis | Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture. We present a 43-y... | Thrombosis | Thromboses Thrombosis Thrombus | Formation and development of a thrombus or blood clot in the blood vessel.
| MESH:D013927 |
paclitaxel | Formation of coronary aneurysm is a rare complication of stenting with bare metal stents, but based on experimental studies drug-eluting stents may induce toxic effects on the vessel wall with incomplete stent apposition, aneurysm formation and with the potential of stent thrombosis or vessel rupture. We present a 43-y... | Paclitaxel | 7 epi Taxol 7-epi-Taxol Anzatax Bris Bristol-Myers Brand of Paclitaxel Squibb Bull Ivax Lemery NSC 125973 NSC-125973 NSC125973 Onxol (4 alpha)-Isomer Paxene Praxel A | A cyclodecane isolated from the bark of the Pacific yew tree, TAXUS BREVIFOLIA. It stabilizes MICROTUBULES in their polymerized form leading to cell death.
| MESH:D017239 |
urotensin-II | Behavioral effects of urotensin-II centrally administered in mice. | Urotensins | Urotensins | Teleost hormones. A family of small peptides isolated from urophyses of bony fishes. They have many different physiological effects, including long-lasting hypotensive activity and have been proposed as antihypertensives. There are at least four different compounds: urotensin I, urotensin II, urotensin III, and urotens... | MESH:D014579 |
Urotensin-II | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Urotensins | Urotensins | Teleost hormones. A family of small peptides isolated from urophyses of bony fishes. They have many different physiological effects, including long-lasting hypotensive activity and have been proposed as antihypertensives. There are at least four different compounds: urotensin I, urotensin II, urotensin III, and urotens... | MESH:D014579 |
U-II | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Urotensins | Urotensins | Teleost hormones. A family of small peptides isolated from urophyses of bony fishes. They have many different physiological effects, including long-lasting hypotensive activity and have been proposed as antihypertensives. There are at least four different compounds: urotensin I, urotensin II, urotensin III, and urotens... | MESH:D014579 |
hypertension | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Hypertension | Blood Pressure High Pressures Hypertension | Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| MESH:D006973 |
bradycardia | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Bradycardia | Bradyarrhythmia Bradyarrhythmias Bradycardia Bradycardias | Cardiac arrhythmias that are characterized by excessively slow HEART RATE, usually below 50 beats per minute in human adults. They can be classified broadly into SINOATRIAL NODE dysfunction and ATRIOVENTRICULAR BLOCK.
| MESH:D001919 |
apomorphine | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Apomorphine | Aguettant Brand of Apomorphine Hydrochloride Anhydrous Apokinon Apomorphin Teclapharm Apomorphin-Teclapharm ApomorphinTeclapharm Chloride Hemihydrate Britaject Britannia | A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.
| MESH:D001058 |
penile erection | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Penile Diseases | Disease Penile Penis Diseases | Pathological processes involving the PENIS or its component tissues.
| MESH:D010409 |
corticosterone | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Corticosterone | Corticosterone | An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437)
| MESH:D003345 |
psychiatric disorders | Urotensin-II (U-II) receptors are widely distributed in the central nervous system. Intracerebroventricular (i.c.v.) injection of U-II causes hypertension and bradycardia and stimulates prolactin and thyrotropin secretion. However, the behavioral effects of centrally administered U-II have received little attention. In... | Mental Disorders | Behavior Disorders Diagnosis Psychiatric Disorder Mental | Psychiatric illness or diseases manifested by breakdowns in the adaptational process expressed primarily as abnormalities of thought, feeling, and behavior producing either distress or impairment of function.
| MESH:D001523 |
dysphonia | Recurrent dysphonia and acitretin. | Dysphonia | Dysphonia Hyperkinetic Organic Tremor Spastic Neurologic Adducter Phonation Disorder Disorders | Difficulty and/or pain in PHONATION or speaking.
| MESH:D055154 |
acitretin | Recurrent dysphonia and acitretin. | Acitretin | 13-cis-Acitretin Acitretin Andreu Brand Roche (Z,E,E,E)-Isomer of Etretin Hoffmann La Hoffmann-La Isoacitretin Isoetretin Neotigason Ro 10-1670 101670 13-7652 137652 Ro-10-1670 Ro-13-7652 Ro101670 Ro137652 Soriatane | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
| MESH:D017255 |
dysphonia | We report the case of a woman complaining of dysphonia while she was treated by acitretin. Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced. To our knowledge, this is the first case of acitretin-induced dysphonia. This effect may be related to the pharmacological effec... | Dysphonia | Dysphonia Hyperkinetic Organic Tremor Spastic Neurologic Adducter Phonation Disorder Disorders | Difficulty and/or pain in PHONATION or speaking.
| MESH:D055154 |
acitretin | We report the case of a woman complaining of dysphonia while she was treated by acitretin. Her symptoms totally regressed after drug withdrawal and reappeared when acitretin was reintroduced. To our knowledge, this is the first case of acitretin-induced dysphonia. This effect may be related to the pharmacological effec... | Acitretin | 13-cis-Acitretin Acitretin Andreu Brand Roche (Z,E,E,E)-Isomer of Etretin Hoffmann La Hoffmann-La Isoacitretin Isoetretin Neotigason Ro 10-1670 101670 13-7652 137652 Ro-10-1670 Ro-13-7652 Ro101670 Ro137652 Soriatane | An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.
| MESH:D017255 |
pain | Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans. | Pain | Ache Aches Burning Pain Pains Crushing Migratory Radiating Splitting Physical Suffering Sufferings | An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| MESH:D010146 |
pain | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Pain | Ache Aches Burning Pain Pains Crushing Migratory Radiating Splitting Physical Suffering Sufferings | An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.
| MESH:D010146 |
tissue injury | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Soft Tissue Injuries | Injuries Soft Tissue Injury | Injuries of tissue other than bone. The concept is usually general and does not customarily refer to internal organs or viscera. It is meaningful with reference to regions or organs where soft tissue (muscle, fat, skin) should be differentiated from bones or bone tissue, as "soft tissue injuries of the hand".
| MESH:D017695 |
secondary hyperalgesia | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Hyperalgesia | Allodynia Mechanical Tactile Thermal Allodynias Hyperalgesia Primary Secondary Hyperalgesias Hyperalgesic Sensations | An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.
| MESH:D006930 |
Secondary hyperalgesia | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Hyperalgesia | Allodynia Mechanical Tactile Thermal Allodynias Hyperalgesia Primary Secondary Hyperalgesias Hyperalgesic Sensations | An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.
| MESH:D006930 |
neurogenic hyperalgesia | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Hyperalgesia | Allodynia Mechanical Tactile Thermal Allodynias Hyperalgesia Primary Secondary Hyperalgesias Hyperalgesic Sensations | An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.
| MESH:D006930 |
neuropathic pain | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Neuralgia | Atypical Neuralgia Neuralgias Iliohypogastric Nerve Ilioinguinal Pain Paroxysmal Pains Perineal Stump Supraorbital Vidian Neurodynia Neurodynias Neuropathic | Intense or aching pain that occurs along the course or distribution of a peripheral or cranial nerve.
| MESH:D009437 |
hyperalgesia | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Hyperalgesia | Allodynia Mechanical Tactile Thermal Allodynias Hyperalgesia Primary Secondary Hyperalgesias Hyperalgesic Sensations | An increased sensation of pain or discomfort produced by mimimally noxious stimuli due to damage to soft tissue containing NOCICEPTORS or injury to a peripheral nerve.
| MESH:D006930 |
gabapentin | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | gabapentin | 1-(aminomethyl)cyclohexaneacetic acid Apo-Gabapentin Convalis Gabapentin Hexal Stada Gabapentin-ratiopharm Neurontin Novo-Gabapentin PMS-Gabapentin gabapentin | MESH:C040029 | |
capsaicin | Abnormal processing of somatosensory inputs in the central nervous system (central sensitization) is the mechanism accounting for the enhanced pain sensitivity in the skin surrounding tissue injury (secondary hyperalgesia). Secondary hyperalgesia shares clinical characteristics with neurogenic hyperalgesia in patients ... | Capsaicin | 8 Methyl N Vanillyl 6 Nonenamide 8-Methyl-N-Vanillyl-6-Nonenamide Alacan Brand of Capsaicin Antiphlogistine Rub A-535 Axsain Capsaicine Capsicum Farmaya Capsidol Capsin Capzasin Carter Horner Centrum Elan Flemming Gelcen Katrum Link Medicis NGX 4010 NGX-4010 NGX4010 Smaller Thompson Vinas Zacin Zostrix | An alkylamide found in CAPSICUM that acts at TRPV CATION CHANNELS.
| MESH:D002211 |
MDMA | MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. | N-Methyl-3,4-methylenedioxyamphetamine | Ecstasy (Drug) Hydrochloride N-Methyl-3,4-methylenedioxyamphetamine MDMA Methylenedioxymethamphetamine N Methyl 3,4 methylenedioxyamphetamine | An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| MESH:D018817 |
impaired social and emotional judgement processes | MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. | Cognition Disorders | Cognition Disorders Disorder Overinclusion | Disturbances in the mental process related to thinking, reasoning, and judgment.
| MESH:D003072 |
memory deficits | In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy). The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on "prefrontal" mediated social and emo... | Memory Disorders | Age Related Memory Disorders Age-Related Disorder Cognitive Retention Deficit Deficits Semantic Spatial Loss Losses | Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
| MESH:D008569 |
MDMA | In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy). The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on "prefrontal" mediated social and emo... | N-Methyl-3,4-methylenedioxyamphetamine | Ecstasy (Drug) Hydrochloride N-Methyl-3,4-methylenedioxyamphetamine MDMA Methylenedioxymethamphetamine N Methyl 3,4 methylenedioxyamphetamine | An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| MESH:D018817 |
3,4-methylenedioxymethamphetamine | In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy). The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on "prefrontal" mediated social and emo... | N-Methyl-3,4-methylenedioxyamphetamine | Ecstasy (Drug) Hydrochloride N-Methyl-3,4-methylenedioxyamphetamine MDMA Methylenedioxymethamphetamine N Methyl 3,4 methylenedioxyamphetamine | An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| MESH:D018817 |
ecstasy | In recent years working memory deficits have been reported in users of MDMA (3,4-methylenedioxymethamphetamine, ecstasy). The current study aimed to assess the impact of MDMA use on three separate central executive processes (set shifting, inhibition and memory updating) and also on "prefrontal" mediated social and emo... | N-Methyl-3,4-methylenedioxyamphetamine | Ecstasy (Drug) Hydrochloride N-Methyl-3,4-methylenedioxyamphetamine MDMA Methylenedioxymethamphetamine N Methyl 3,4 methylenedioxyamphetamine | An N-substituted amphetamine analog. It is a widely abused drug classified as a hallucinogen and causes marked, long-lasting changes in brain serotonergic systems. It is commonly referred to as MDMA or ecstasy.
| MESH:D018817 |
citrate | Severe citrate toxicity complicating volunteer apheresis platelet donation. | sodium citrate | Citra ph anhydrous sodium citrate dihydrate trisodium | MESH:C102006 | |
toxicity | Severe citrate toxicity complicating volunteer apheresis platelet donation. | Drug-Related Side Effects and Adverse Reactions | Adverse Drug Event Events Reaction Reactions Related Side Effects and Effect Toxicities Toxicity Drug-Related Drugs of | Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| MESH:D064420 |
citrate | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | sodium citrate | Citra ph anhydrous sodium citrate dihydrate trisodium | MESH:C102006 | |
toxicity | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Drug-Related Side Effects and Adverse Reactions | Adverse Drug Event Events Reaction Reactions Related Side Effects and Effect Toxicities Toxicity Drug-Related Drugs of | Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| MESH:D064420 |
hypertension | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Hypertension | Blood Pressure High Pressures Hypertension | Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| MESH:D006973 |
hyperlipidemia | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Hyperlipidemias | Hyperlipemia Hyperlipemias Hyperlipidemia Hyperlipidemias Lipemia Lipemias Lipidemia Lipidemias | Conditions with excess LIPIDS in the blood.
| MESH:D006949 |
depression | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Depressive Disorder | Depression Endogenous Neurotic Unipolar Depressions Depressive Disorder Disorders Neuroses Neurosis Syndrome Syndromes Melancholia Melancholias | An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent.
| MESH:D003866 |
bumetanide | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Bumetanide | AstraZeneca Brand of Bumetanide Atlantis Bumedyl Farmacusi Grossmann Leo Roche Senosiain Bumethanide Bumex Burinex Drenural Fordiuran Miccil PF 1593 PF-1593 PF1593 | A sulfamyl diuretic.
| MESH:D002034 |
pravastatin | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Pravastatin | Apo Pravastatin Apo-Pravastatin Apotex Brand of Sodium Aventis Bristacol Bristol-Myers Squibb CS 514 CS-514 CS514 Elisor Eptastatin Esteve Juste Lin Lin-Pravastatin Linson Pharma Lipemol Liplat Lipostat Mevalotin Nu Nu-Pharma Nu-Pravastatin Prareduct Pravachol Pravacol Pravasin Monosodium Salt (6 beta)-Isomer tert Octy... | An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
| MESH:D017035 |
paroxetine | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Paroxetine | Acetate Paroxetine Anhydrous Hydrochloride Aropax BRL 29060 BRL-29060 BRL29060 FG 7051 FG-7051 FG7051 Hemihydrate Maleate cis-(+)-Isomer cis-(-)-Isomer trans-(+)-Isomer Paxil Seroxat | A serotonin uptake inhibitor that is effective in the treatment of depression.
| MESH:D017374 |
tetany | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Tetany | Neonatal Tetanies Tetany Spasmophilia Spasmophilias Tetanilla Tetanillas | A disorder characterized by muscle twitches, cramps, and carpopedal spasm, and when severe, laryngospasm and seizures. This condition is associated with unstable depolarization of axonal membranes, primarily in the peripheral nervous system. Tetany usually results from HYPOCALCEMIA or reduced serum levels of MAGNESIUM ... | MESH:D013746 |
calcium gluconate | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Calcium Gluconate | 3M Brand of Calcium Gluconate Monohydrate Braun CBG Calciofon Calcipot Calcivitol Calglucon Chaix et du Marais Coophavet Ebucin Flopak Plain Fresenius Kabi Glucal Glucobiogen de Lavoisier Gluconato Calc Merial Pharmtech | The calcium salt of gluconic acid. The compound has a variety of uses, including its use as a calcium replenisher in hypocalcemic states.
| MESH:D002125 |
muscle contractions | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Crisponi syndrome | CNTF Receptor-Related Disorders Cold-Induced Sweating Syndrome Crisponi syndrome Sohar-Crisponi | MESH:C536214 | |
calcium | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Calcium | Blood Coagulation Factor IV Calcium | A basic element found in nearly all organized tissues. It is a member of the alkaline earth family of metals with the atomic symbol Ca, atomic number 20, and atomic weight 40. Calcium is the most abundant mineral in the body and combines with phosphorus to form calcium phosphate in the bones and teeth. It is essential ... | MESH:D002118 |
sodium citrate | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | sodium citrate | Citra ph anhydrous sodium citrate dihydrate trisodium | MESH:C102006 | |
hypocalcemia | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Hypocalcemia | Hypocalcemia Hypocalcemias | Reduction of the blood calcium below normal. Manifestations include hyperactive deep tendon reflexes, Chvostek's sign, muscle and abdominal cramps, and carpopedal spasm. (Dorland, 27th ed)
| MESH:D006996 |
loop diuretic | We report a case of severe citrate toxicity during volunteer donor apheresis platelet collection. The donor was a 40-year-old female, first-time apheresis platelet donor. Past medical history was remarkable for hypertension, hyperlipidemia, and depression. Reported medications included bumetanide, pravastatin, and paro... | Sodium Potassium Chloride Symporter Inhibitors | Bumetanide Sensitive Na K Cl Transporter Inhibitors Na-K-Cl-Transporter Ceiling Diuretics High Loop Na-K-CL Symporter CL Sodium Potassium Chloride Cotransporter | Agents that inhibit SODIUM-POTASSIUM-CHLORIDE SYMPORTERS which are concentrated in the thick ascending limb at the junction of the LOOP OF HENLE and KIDNEY TUBULES, DISTAL. They act as DIURETICS. Excess use is associated with HYPOKALEMIA and HYPERGLYCEMIA.
| MESH:D049994 |
Proteinuria | Proteinuria after conversion to sirolimus in renal transplant recipients. | Proteinuria | Proteinuria Proteinurias | The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| MESH:D011507 |
sirolimus | Proteinuria after conversion to sirolimus in renal transplant recipients. | Sirolimus | AY 22 989 22-989 22989 I 2190A I-2190A I2190A Rapamune Rapamycin Sirolimus Wyeth Brand of | A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic p... | MESH:D020123 |
Sirolimus | Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL c... | Sirolimus | AY 22 989 22-989 22989 I 2190A I-2190A I2190A Rapamune Rapamycin Sirolimus Wyeth Brand of | A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic p... | MESH:D020123 |
SRL | Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL c... | Sirolimus | AY 22 989 22-989 22989 I 2190A I-2190A I2190A Rapamune Rapamycin Sirolimus Wyeth Brand of | A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic p... | MESH:D020123 |
proteinuria | Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL c... | Proteinuria | Proteinuria Proteinurias | The presence of proteins in the urine, an indicator of KIDNEY DISEASES.
| MESH:D011507 |
sirolimus | Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL c... | Sirolimus | AY 22 989 22-989 22989 I 2190A I-2190A I2190A Rapamune Rapamycin Sirolimus Wyeth Brand of | A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic p... | MESH:D020123 |
chronic allograft nephropathy | Sirolimus (SRL) is a new, potent immunosuppressive agent. More recently, proteinuria has been reported as a consequence of sirolimus therapy, although the mechanism has remained unclear. We retrospectively examined the records of 25 renal transplant patients, who developed or displayed increased proteinuria after SRL c... | Renal Insufficiency, Chronic | Chronic Kidney Disease Diseases Insufficiencies Insufficiency Renal | Conditions in which the KIDNEYS perform below the normal level for more than three months. Chronic kidney insufficiency is classified by five stages according to the decline in GLOMERULAR FILTRATION RATE and the degree of kidney damage (as measured by the level of PROTEINURIA). The most severe form is the end-stage ren... | MESH:D051436 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.